A Study of Anlotinib Hydrochloride Capsule Combined With AK105 Injection in Subject With Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma
研究单位：[1]Chia Tai Tianqing Pharmaceutical Group Co.,Ltd.[2]The First Affiliated Hospital of Anhui Medical University Hefei,Anhui,China,230022[3]Beijing Shijitan Hospital Affiliated to Capital Medical University Beijing,Beijing,China,100038[4]The Sixth Medical Center of PLA General Hospital Beijing,Beijing,China,100048[5]Peking University Shougang Hospital Beijing,Beijing,China,100144[6]Tongji Hospital,Tongji Medical College,Huazhong University of Science & Technology Wuhan,Hubei,China,430030[7]Hubei Cancer Hospital Wuhan,Hubei,China,430079
研究目的：
This is a randomized, controlled, open-label, multicenter study to evaluate efficacy of AK105 injection combined with Anlotinib Hydrochloride Capsules versus standard second-line chemotherapy. Patients are treated with AK105 injection combined with Anlotinib Hydrochloride Capsules or standard second-line chemotherapy, with 1:1 random ratio.
